Stockscreener 앱 받기
6.66
4.31%
-0.30
시간 외 거래:
6.66
전일 마감가:
$6.96
열려 있는:
$6.81
하루 거래량:
4,370
Relative Volume:
0.13
시가총액:
$46.86M
수익:
-
순이익/손실:
$-31.48M
주가수익비율:
-6.4038
EPS:
-1.04
순현금흐름:
$-28.71M
1주 성능:
-6.46%
1개월 성능:
+13.27%
6개월 성능:
+40.21%
1년 성능:
-62.69%
1일 변동 폭
$6.61
$7.02
1주일 범위
$6.50
$7.70
52주 변동 폭
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
명칭
Forte Biosciences Inc
전화
(310) 618-6994
주소
3060 PEGASUS PARK DRIVE, DALLAS, CA
FBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
6.66 | 46.86M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-21 | 개시 | TD Cowen | Buy |
| 2024-04-08 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | 업그레이드 | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | 다운그레이드 | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | 다운그레이드 | Truist | Buy → Hold |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-03-26 | 개시 | Citigroup | Buy |
| 2020-08-28 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | 개시 | Truist | Buy |
모두보기
Forte Biosciences Inc 주식(FBRX)의 최신 뉴스
Geode Capital Management LLC Boosts Stock Position in AmpliTech Group, Inc. (NASDAQ:AMPG) - Defense World
Geode Capital Management LLC Increases Position in Forte Biosciences, Inc. (NASDAQ:FBRX) - Defense World
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Meta Doubles Down on AI: Is the Stock Ready to Skyrocket? - The Globe and Mail
Forte Biosciences sets Annual Meeting for May 29 By Investing.com - Investing.com Canada
Forte Biosciences sets Annual Meeting for May 29 - Investing.com Australia
Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
Mr. Ethan Billings recommends paying close attention to biotech stocks - FinancialContent
Profit from Trump’s Tariff Playbook with TipRanks’ New Comparison Tool - The Globe and Mail
Nvidia and Broadcom Helped Propel This ETF 18% Higher in a Single Day. Here's Why It's Still a Buy Now. - The Globe and Mail
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Analysts Issue Forecasts for FBRX Q2 Earnings - Defense World
Equities Analysts Offer Predictions for FBRX FY2025 Earnings - Defense World
(FBRX) Investment Analysis - news.stocktradersdaily.com
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy - MSN
Chardan Capital Issues Pessimistic Forecast for Forte Biosciences (NASDAQ:FBRX) Stock Price - Defense World
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Chardan Adjusts Price Target on Forte Biosciences to $61 From $64, Maintains Buy Rating - MarketScreener
Forte Biosciences Reports 2024 Progress and Financials - TipRanks
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans? - Yahoo
Forte's Celiac Treatment Shows Promise: Zero Dropouts and $58.4M War Chest - Stock Titan
Forte Biosciences, Inc. Announces Results and Provides Clinical Update - Bluefield Daily Telegraph
Forte Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Forte Biosciences Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - MarketScreener
Forte Biosciences, Inc. SEC 10-K Report - TradingView
Forte Biosciences Inc. (FBRX) reports earnings - Quartz
(FBRX) Long Term Investment Analysis - news.stocktradersdaily.com
Pre-market Movers: PTPI, ACON, HUMA, TNON... - RTTNews
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Pre-market Movers: OPTN, WINT, AKBA, GCTK... - RTTNews
FORTE BIOSCIENCES Earnings Preview: Recent $FBRX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Forte Biosciences Inc expected to post a loss of $3.27 a shareEarnings Preview - TradingView
Forte Biosciences, Inc. (NASDAQ:FBRX) Sees Large Drop in Short Interest - Defense World
Forte Biosciences (FBRX) Expected to Announce Quarterly Earnings on Monday - Defense World
Stock Traders Purchase Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - The AM Reporter
Traders Purchase High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update - MarketBeat
Forte Biosciences Stock Down 20% But Insiders Still In US$92k Profit - Simply Wall St
Pre-market Movers: ISPC, TH, IVVD, TOVX... - RTTNews
(FBRX) On The My Stocks Page - news.stocktradersdaily.com
Stock Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Evelo Biosciences Target of Unusually Large Options Trading (NASDAQ:EVLO) - Defense World
One Forte Biosciences Insider Raised Stake By 273% In Previous Year - Yahoo Finance
Best Stocks Under $20 Right Now - Benzinga
Where are the Opportunities in (FBRX) - Stock Traders Daily
Stock Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
iA Financial Group Announces the Acquisition of Global Warranty - The Globe and Mail
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings -February 03, 2025 at 09:03 am EST - Marketscreener.com
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings - Business Wire
Forte Biosciences Inc (FBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):